Ignite Creation Date:
2024-05-05 @ 6:34 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00509769
Status:
COMPLETED
Last Update Posted:
2013-04-02
First Post:
2007-07-27
Brief Title:
A Study of Trastuzumab Emtansine Trastuzumab-MCC-DM1 Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 HER2-Positive Metastatic Breast Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Organization Data
Organization:
Genentech Inc
Class:
INDUSTRY
Study ID:
TDM4258g
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Genentech Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None